Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Effects on mice of numbers of animals per cage: an 18-month study (preliminary results).
- M. Chvédoff, M. R. Clarke, J. Faccini, E. Irisarri, A. Monro
- Chemistry, Medicine
- Archives of toxicology. Supplement. = Archiv fur…
- 1980
Mice were housed 1, 2, 4, or 8 per cage for 18 months. The more densely housed groups showed markedly reduced food consumption, slightly decreased mean body weights, and a smaller variance of body… Expand
Hepatic foci of cellular and enzymatic alteration and nodules in rats treated with clofibrate or diethylnitrosamine followed by phenobarbital: their rate of onset and their reversibility.
- P. Greaves, E. Irisarri, A. Monro
- Biology, Medicine
- Journal of the National Cancer Institute
- 1 March 1986
The histologic appearance and cytochemical characteristics of foci of hepatic cellular alteration, hepatic nodules, and hepatocellular carcinomas occurring in male Sprague-Dawley rats treated with… Expand
Effects of housing conditions on food intake, body weight and spontaneous lesions in mice. A review of the literature and results of an 18-month study.
- M. Chvédoff, M. R. Clarke, E. Irisarri, J. Faccini, A. Monro
- Medicine
- Food and cosmetics toxicology
- 1980
Abstract Mice were housed in groups of one, two, four or eight/cage for 18 months. The more densely housed groups showed markedly reduced food consumption, slightly decreased mean body weights, and a… Expand
A carcinogenicity study in mice of a beta-adrenergic antagonist, primidolol; increased total tumour incidence without tissue specificity.
- J. Faccini, E. Irisarri, A. Monro
- Biology, Medicine
- Toxicology
- 1981
The beta-adrenergic blocking agent, primidolol hydrochloride, was administered, mixed in the diet, to mice (CD-1, Charles River, France) for 18 months. Experimental groups comprised untreated… Expand
The relationship of cytochemical changes to the development of chemically induced hepatocellular carcinoma
- E. Irisarri
- Chemistry
- 1985
The morphological and cytochemical changes occurring in liver of male Sprague-Dawley rats receiving clofibrate, diethylnitrosamine (DENA) followed by phenobarbital (PB) and PB alone were studied… Expand
- 3
[Post-natal parasitic infection of piglets in contact with infected mothers. a study of 20 sows and 164 piglets, 42 of which were killed at weaning (author's transl)].
- J. Raynaud, E. Irisarri, J. Sennelier
- Biology, Medicine
- Folia veterinaria Latina
- 1 July 1975
A cytochemical study of the livers of rats treated with diethylnitrosamine/phenobarbital, with benzidine/phenobarbital, with phenobarbital, or with clofibrate.
- P. Mompon, P. Greaves, E. Irisarri, A. Monro, J. Bridges
- Chemistry, Medicine
- Toxicology
- 30 October 1987
Male Sprague-Dawley rats were treated with clofibrate (CLOF) in the diet for 2 years or with 4 i.p. injections of either diethylnitrosamine (DEN) or benzidine (BZ) followed by phenobarbital (PB) in… Expand
Rat Urinary Bladder Hyperplasia Induced by Oral Administration of Carbonic Anhydrase Inhibitors
- S. Molon-Noblot, C. Boussiquet-Leroux, +4 authors P. Duprat
- Chemistry, Medicine
- Toxicologic pathology
- 1 January 1992
The carbonic anhydrase inhibitors, acetazolamide and MK-0927, were given by oral route to male Sprague-Dawley rats at 200 mg/kg/day and 25 mg/kg/day, respectively, for up to 4 weeks. Sequential… Expand
Dazoxiben, a Prototype Inhibitor of Thromboxane Synthesis, has Little Toxicity in Laboratory Animals
- E. Irisarri, M. J. Kessedjian, +5 authors Y. Rabémampianina
- Biology, Medicine
- Human toxicology
- 1 May 1985
1 Dazoxiben, an orally active specific inhibitor of thromboxane synthetase, was administered by mouth daily to dogs and rats for 6 months. 2 Dogs showed no evidence of toxicity up to 300 mg day-1… Expand
The Preclinical Toxicity of Dazoxiben: A Specific Inhibitor of Thromboxane A2 Synthetase
- E. Irisarri, M. J. Kessedjian, +5 authors Y. Rabémampianina
- Medicine
- 1984
The recent discovery of highly selective inhibitors of thromboxane synthetase has opened exciting new therapeutic possibilities in cardiovascular disease, ranging from peripheral vascular disorders,… Expand